Oasmia Pharmaceuticals, which develops innovative drugs within human and veterinary oncology, announced this week that the first patient to take part in the Phase 1 clinical trial for Docecal, the company’s groundbreaking cancer treatment, has been enrolled.
The trial for the new drug, which was approved for trials in December of last year, will be conducted on an international scale.
Docecal is a form of docetaxel, one of the most widely used anti-cancer substances in the industry, that is both a nanoparticle and water-soluble that has been combined with Oasmia’s patented XR17 technology. Docetaxel is used to treat multiple types of cancer, including prostate, breast, lung and stomach. It is used in the cytostatic Taxotere, where it is the most active substance. Taxotere is marketed by Sanofi-Aventis.
In 2009, Sanofi-Aventis accrued $3 billion in sales for Taxotere before the patent expired in 2010. Taxotere is estimated to continue generating these types of sales figures.
Oasmia enrolls first patient into Phase 1 Docecal trial
Alerts Sign-up